Search

Your search keyword '"Gladman, Dafna D"' showing total 872 results
Start Over Author "Gladman, Dafna D" Search Limiters Academic (Peer-Reviewed) Journals
872 results on '"Gladman, Dafna D"'

6. OMERACT systemic lupus erythematosus domain survey

Author

Nielsen, Wils, Strand, Vibeke, Simon, Lee, Pinsker, Ellie, Bonilla, Dennisse, Morand, Eric, Thumboo, Julian, Aringer, Martin, Mosca, Marta, Bruce, Ian, Parodis, Ioannis, Kim, Alfred, Desai, Maya, Enman, Yvonne, Shea, Beverley, Wallace, Daniel J., Chaichian, Yashaar, Navarra, Sandra, Aranow, Cynthia, Mackay, Meggan, Trotter, Kimberly, Tayer-Shifman, Oshrat E., Duarte-García, Alí, Shan Tam, Lai, Ugarte-Gil, Manuel F., Pons-Estel, Guillermo J., Reynolds, John A., Nikpour, Mandana, Hoi, Alberta, Romero-Diaz, Juanita, Aggarwal, Amita, Mok, Chi Chiu, Fujio, Keishi, Ramsey-Goldman, Rosalind, Gladman, Dafna D., Arnaud, Laurent, Bultink, Irene E.M., Ruiz-Irastorza, Guillermo, Inês, Luís Sousa, Appenzeller, Simone, Dobrowolski, Chrisanna, Clarke, Ann Elaine, Kamen, Diane L., Barraclough, Michelle, Tani, Chiara, Gómez-Puerta, Jose A, Werth, Victoria P., Katz, Patti, Nowrouzi-Kia, Behdin, Johnson, Sindhu R., Drucker, Aaron M., and Touma, Zahi

Published
2024
Full Text
View/download PDF

7. Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation

Author

Calabrese, Cassandra, Desai, Seemal R., Duffin, Kristina C., Feldman, Steven R., Gladman, Dafna D., Glick, Brad P., Han, George, Harris, Jason, Hawkes, Jason E., Hsu, Sylvia, Huang, Margaret Y., Kalb, Robert E., Kircik, Leon H., Koo, John, Lewitt, G. Michael, Liao, Wilson J., Liu, Clive, Merola, Joseph F., Prussick, Ronald B., Reddy, Soumya M., Schwartzman, Sergio, Smith, Jessica N., Soung, Jennifer, Van Voorhees, Abby S., Wallace, Elizabeth B., Weinberg, Jeffrey M., Lee, Lara Wine, Yamauchi, Paul S., Armstrong, April W., Elston, Carly A., Elewski, Boni E., Ferris, Laura K., Gottlieb, Alice B., and Lebwohl, Mark G.

Published
2024
Full Text
View/download PDF

9. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial

Author

Curtis, Jeffrey R., McInnes, Iain B., Rahman, Proton, Gladman, Dafna D., Peterson, Steven, Agarwal, Prasheen, Yang, Feifei, Kollmeier, Alexa P., Hsia, Elizabeth C., Shiff, Natalie J., Zhou, Bei, Han, Chenglong, Shawi, May, Tillett, William, and Mease, Philip J.

Published
2022
Full Text
View/download PDF

11. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Author

Merola, Joseph F, Landewé, Robert, McInnes, Iain B, Mease, Philip J, Ritchlin, Christopher T, Tanaka, Yoshiya, Asahina, Akihiko, Behrens, Frank, Gladman, Dafna D, Gossec, Laure, Gottlieb, Alice B, Thaçi, Diamant, Warren, Richard B, Ink, Barbara, Assudani, Deepak, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, and Coates, Laura C

Published
2023
Full Text
View/download PDF

12. Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Author

Clarke, Ann E., Hanly, John G., Urowitz, Murray B., St. Pierre, Yvan, Gordon, Caroline, Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Sanchez‐Guerrero, Jorge, Bernatsky, Sasha, Wallace, Daniel J., Isenberg, David A., Rahman, Anisur, Merrill, Joan T., Fortin, Paul R., Gladman, Dafna D., Bruce, Ian N., Petri, Michelle, Ginzler, Ellen M., Dooley, Mary Anne, Ramsey‐Goldman, Rosalind, Manzi, Susan, Jönsen, Andreas, Alarcón, Graciela S., Van Vollenhoven, Ronald F., Aranow, Cynthia, Mackay, Meggan, Ruiz‐Irastorza, Guillermo, Lim, S. Sam, Inanc, Murat, Kalunian, Kenneth C., Jacobsen, Soren, Peschken, Christine A., Kamen, Diane L., Askanase, Anca, and Farewell, Vernon

Published
2023
Full Text
View/download PDF

14. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Author

Johnson, Sindhu R., Gladman, Dafna D., Brunner, Hermine I., Isenberg, David, Clarke, Ann E., Barber, Megan R. W., Arnaud, Laurent, Fortin, Paul R., Mosca, Marta, Voskuyl, Alexandre E., Manzi, Susan, Aranow, Cynthia, Askanase, Anca, Alarcón, Graciela S., Bae, Sang‐Cheol, Costedoat‐Chalumeau, Nathalie, English, Jessica A., Pons‐Estel, Guillermo J., Pons‐Estel, Bernardo A., Gilman, Rebecca, Ginzler, Ellen M., Hanly, John G., Jacobsen, Soren, Kalunian, Kenneth, Kamen, Diane L., Lambalgen, Chynace, Legge, Alexandra, Lim, S. Sam, Mak, Anselm, Morand, Eric F., Peschken, Christine A., Petri, Michelle, Rahman, Anisur, Ramsey‐Goldman, Rosalind, Reynolds, John A., Romero‐Diaz, Juanita, Ruiz‐Irastorza, Guillermo, Sanchez‐Guerrero, Jorge, Svenungsson, Elisabet, Touma, Zahi, Urowitz, Murray, Vinet, Evelyne, van Vollenhoven, Ronald F., Waldhauser, Heather, Wallace, Daniel J., Zoma, Asad, and Bruce, Ian N.

Published
2023
Full Text
View/download PDF

15. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

Author

Appenzeller, Simone, Aranow, Cynthia, Askanase, Anca, Avcin, Tadej, Bae, Sang-Cheol, Bertsias, George, Bonfa, Eloisa, Cairoli, Ernesto, Cardiel, Mario H, Cervera, Ricard, Chasset, François, Chizzolini, Carlo, Clarke, Ann E, Conti, Fabrizio, Costedoat-Chalumeau, Nathalie, Czirják, László, Doria, Andrea, Dörner, Thomas, Espinosa, Gerard, Fischer-Betz, Rebecca, Garcìa, Mercedes, Gladman, Dafna D, González, Luis A, Gunnarsson, Iva, Hamijoyo, Laniyati, Hanly, John G, Hasni, Sarfaraz A, Houssiau, Frédéric A, Inanç, Murat, Inês, Luís S, Isenberg, David, Jacobsen, Soren, Jan Wu, Yeong-Jian, Kaneko, Yuko, Katsumata, Yasuhiro, Lau, Chak S, Legge, Alexandra C, Lerang, Karoline, Limper, Maarten, Louthrenoo, Worawit, Luo, Shue-Fen, Marinho, António, Massardo, Loreto, Mathian, Alexis, Mosca, Marta, Nikpour, Mandana, Pego-Reigosa, José M, Peschken, Christine A, Pons-Estel, Bernardo A, Pons-Estel, Guillermo J, Rahman, Anisur, Rednic, Simona, Ribi, Camillo, Ruiz-Irastorza, Guillermo, Sato, Emilia I, Saxena, Amit, Schneider, Matthias, Sebastiani, Gian Domenico, Strand, Vibeke, Svenungsson, Elisabet, Tanaka, Yoshiya, Tazi Mezalek, Zoubida, Tee, Michael L, Tincani, Angela, Touma, Zahi, Troldborg, Anne, Vasconcelos, Carlos, Vinet, Évelyne, Vital, Edward M, Voskuyl, Alexandre E, Voss, Anne, Wallace, Daniel, Ward, Michael, Zamora, Leonid D, Piga, Matteo, Chessa, Elisabetta, Morand, Eric F, Ugarte-Gil, Manuel F, Tektonidou, Maria, van Vollenhoven, Ronald, Petri, Michelle, and Arnaud, Laurent

Published
2022
Full Text
View/download PDF

17. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial

Author

Gladman, Dafna D., Mease, Philip J., Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Xu, Stephen, Quinn, Sean T., Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S., Kavanaugh, Arthur, Deodhar, Atul, Østergaard, Mikkel, and Baraliakos, Xenofon

Published
2022
Full Text
View/download PDF

19. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses.

Author

FitzGerald, Oliver, Gladman, Dafna D., Mease, Philip J., Ritchlin, Christopher, Smolen, Josef S., Gao, Lu, Hu, Yanhua, Nowak, Miroslawa, Banerjee, Subhashis, and Catlett, Ian

Subjects
*INFLAMMATION prevention, *PSORIATIC arthritis, *PROTEIN-tyrosine kinase inhibitors, *STATISTICAL sampling, *ANTIRHEUMATIC agents, *TREATMENT effectiveness, *RANDOMIZED controlled trials, *SEVERITY of illness index, *CELLULAR signal transduction, *DRUG efficacy, *MATRIX metalloproteinases, *IMMUNOASSAY, *BIOMARKERS, *INTERLEUKINS, *C-reactive protein, *PHARMACODYNAMICS, *EVALUATION
Abstract

Objective: Our objective was to evaluate the association of serum biomarkers with baseline psoriatic arthritis (PsA) disease activity, pharmacodynamic effects of deucravacitinib on biomarker levels, and the relationship between biomarkers and clinical responses to deucravacitinib. Methods: The phase 2 trial (ClinicalTrials.gov identifier: NCT03881059) randomly assigned 203 patients with PsA 1:1:1 to placebo, deucravacitinib at 6 mg once daily (QD), or deucravacitinib at 12 mg QD. Serum biomarkers associated with the interleukin 23 (IL‐23) pathway (IL‐17A, β‐defensin [BD‐2], and IL‐19), type I interferon pathway, inflammation, and collagen matrix turnover were measured by immunoassay. Clinical responses (≥75% improvement from baseline in the Psoriasis Area and Severity Index [PASI75] and ≥20% improvement from baseline in American College of Rheumatology criteria [ACR20] responses) were measured at week 16. Hematologic variables were also assessed. Results: IL‐17A, BD‐2, and IL‐19 had a modest association with PASI scores (r = 0.4, r = 0.56, and r = 0.5, respectively) at baseline. In deucravacitinib groups, IL‐17A, BD‐2, IL‐19, C‐X‐C motif ligand 9 (CXCL9), CXCL10, C‐reactive protein, matrix metalloproteinase 3, and collagen type 4 degradation marker levels were significantly reduced at week 16 versus baseline (P < 0.01); higher levels of IL‐23 pathway–associated biomarkers predicted higher PASI75 and ACR20 response rates in deucravacitinib‐treated patients. Significantly higher PASI75 response rates were seen in patients with high baseline IL‐17A (odds ratio 15.76) and BD‐2 levels (odds ratio 15.41) versus low baseline IL‐17A and BD‐2 levels. Changes in hematologic variables that are characteristic of JAK inhibition were not observed with deucravacitinib. Conclusion: Deucravacitinib significantly impacted biomarkers associated with Tyk2 signaling pathways of key inflammatory cytokines, including IL‐23 and type I interferon, and those related to collagen matrix turnover. These biomarkers may predict treatment responses to deucravacitinib. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis.

Author

Mease, Philip J, Gladman, Dafna D, Merola, Joseph F, Nash, Peter, Grieve, Stacy, Laliman-Khara, Victor, Willems, Damon, Taieb, Vanessa, Prickett, Adam R, and Coates, Laura C

Subjects
*THERAPEUTIC use of immunoglobulins, *THERAPEUTIC use of monoclonal antibodies, *MEDICAL information storage & retrieval systems, *ANTI-inflammatory agents, *PATIENT safety, *PSORIATIC arthritis, *LEFLUNOMIDE, *METHOTREXATE, *ANTIRHEUMATIC agents, *META-analysis, *DESCRIPTIVE statistics, *SYSTEMATIC reviews, *ODDS ratio, *MEDLINE, *JANUS kinases, *PHOSPHODIESTERASE inhibitors, *DRUG efficacy, *MEDICAL databases, *SULFONAMIDES, *NEUROTRANSMITTER uptake inhibitors, *INTERLEUKINS, *CHEMICAL inhibitors
Abstract

Objectives To understand the relative efficacy and safety of bimekizumab, a selective inhibitor of IL-17F in addition to IL-17A, vs other biologic and targeted synthetic DMARDs (b/tsDMARDs) for PsA using network meta-analysis (NMA). Methods A systematic literature review (most recent update conducted on 1 January 2023) identified randomized controlled trials (RCTs) of b/tsDMARDs in PsA. Bayesian NMAs were conducted for efficacy outcomes at Weeks 12–24 for b/tsDMARD-naïve and TNF inhibitor (TNFi)-experienced patients. Safety at Weeks 12–24 was analysed in a mixed population. Odds ratios (ORs) and differences of mean change with the associated 95% credible interval (CrI) were calculated for the best-fitting models, and the surface under the cumulative ranking curve (SUCRA) values were calculated to determine relative rank. Results The NMA included 41 RCTs for 22 b/tsDMARDs. For minimal disease activity (MDA), bimekizumab ranked 1st in b/tsDMARD-naïve patients and 2nd in TNFi-experienced patients. In b/tsDMARD-naïve patients, bimekizumab ranked 6th, 5th and 3rd for ACR response ACR20/50/70, respectively. In TNFi-experienced patients, bimekizumab ranked 1st, 2nd and 1st for ACR20/50/70, respectively. For Psoriasis Area and Severity Index 90/100, bimekizumab ranked 2nd and 1st in b/tsDMARD-naïve patients, respectively, and 1st and 2nd in TNFi-experienced patients, respectively. Bimekizumab was comparable to b/tsDMARDs for serious adverse events. Conclusion Bimekizumab ranked favourably among b/tsDMARDs for efficacy on joint, skin and MDA outcomes, and showed comparable safety, suggesting it may be a beneficial treatment option for patients with PsA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study.

Author

Remalante-Rayco, Patricia, Espiritu, Adrian I, Daghistani, Yassir, Chim, Tina, Atenafu, Eshetu, Keshavarzi, Sareh, Jha, Mayank, Gladman, Dafna D, Oh, Jiwon, Haroon, Nigil, and Inman, Robert D

Subjects
INFLAMMATORY bowel disease diagnosis, RISK assessment, PSORIATIC arthritis, PREDICTION models, ANKYLOSIS, SMOKING, SCIENTIFIC observation, DESCRIPTIVE statistics, LONGITUDINAL method, DEMYELINATION, SPONDYLOARTHROPATHIES, CONFIDENCE intervals, PROPORTIONAL hazards models, DISEASE risk factors
Abstract

Objectives The objectives of this study were to investigate the incidence of demyelinating disease (DD) among SpA patients and to identify risk factors that predict DD in this patient population. Methods Axial SpA (axSpA) and PsA patients were identified from a longitudinal cohort database. Each group was analysed according to the presence or absence of DD. Incidence rates (IRs) of DD were obtained, with competing risk analysis. Cox regression analysis (with Fine and Gray's method) was used to evaluate predictors of DD development. Results Among 2260 patients with follow-up data, we identified 18 DD events, corresponding to an average IR of 31 per 100 000 persons per year for SpA. The IR of DD at 20 years was higher in axSpA than in PsA (1.30% vs 0.13%, P  = 0.01). The risk factors retained in the best predictive model for DD development included ever- (vs never-) smoking [hazard ratio (HR) 2.918, 95% CI 1.037–8.214, P  = 0.0426], axSpA (vs PsA) (HR 8.790, 95% CI 1.242–62.182, P  = 0.0294) and presence (vs absence) of IBD (HR 5.698, 95% CI 2.083–15.589, P  = 0.0007). History of TNF-α inhibitor therapy was not a predictor of DD. Conclusion The overall incidence of DD in this SpA cohort was low. Incident DD was higher in axSpA than in PsA. A diagnosis of axSpA, the presence of IBD, and ever-smoking predicted the development of DD. History of TNF-α inhibitor use was not found to be a predictor of DD in this cohort. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies

Author

Mease, Philip J, Helliwell, Philip S, Gladman, Dafna D, Poddubnyy, Denis, Baraliakos, Xenofon, Chakravarty, Soumya D, Kollmeier, Alexa P, Hsia, Elizabeth C, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Sweet, Kristen, Shawi, May, Karyekar, Chetan S, Deodhar, Atul, and van der Heijde, Désirée

Published
2021
Full Text
View/download PDF

29. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance

Author

Nash, Peter, Mease, Philip J, Fleishaker, Dona, Wu, Joseph, Coates, Laura C, Behrens, Frank, Gladman, Dafna D, Kivitz, Alan J, Wei, James C, Shirinsky, Ivan, Menon, Sujatha, Romero, Ana B, Fallon, Lara, Hsu, Ming-Ann, Wang, Cunshan, and Kanik, Keith S

Published
2021
Full Text
View/download PDF

32. Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA).

Author

Gladman, Dafna D., Chandran, Vinod, Rosen, Cheryl F., Rohekar, Sherry, Boyd, Tristan, Eder, Lihi, Rahman, Proton, Dutz, Jan, Chan, Jonathan, Haydey, Richard P., Barac, Snezana, Laliberté, Marie-Claude, Girard, Tanya, Fournier, Pierre-André, Sutton, Mitchell, Pereira, Daniel, Chim, Tina, Coupal, Louis, and Choquette, Denis

Published
2024
Full Text
View/download PDF

33. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies.

Author

Baraliakos, Xenofon, Gladman, Dafna D, Chakravarty, Soumya D, Gong, Cinty, Shawi, May, Rampakakis, Emmanouil, Kishimoto, Mitsumasa, Soriano, Enrique R, and Mease, Philip J

Subjects
PSORIATIC arthritis, SPONDYLOARTHROPATHIES, DIAGNOSTIC imaging
Abstract

Objective In the absence of axial psoriatic arthritis (axPsA)-specific tools, the BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) are used to assess axial symptoms in patients with PsA. Here, we assessed the performance of BASDAI and ASDAS in patients with PsA. Methods Patients with active PsA in DISCOVER-1 and DISCOVER-2 (ClinicalTrials.gov: NCT03162796 and NCT03158285, respectively) with or without axPsA but with available baseline BASDAI information were analysed; those with investigator-identified axial symptoms and imaging-confirmed sacroiliitis comprised the axPsA cohort. Correlations between BASDAI/ASDAS and clinical variables were assessed with Pearson's coefficient (r). Longitudinal effects of enthesitis (Leeds Enthesitis Index [LEI]), swollen joint count and presence versus absence of axPsA on BASDAI/ASDAS (normalized 0–10 scale) were analysed with mixed models for repeated measures. Results At baseline in the axPsA (n  = 312) and non-axPsA (n  = 124) cohorts, BASDAI scores showed no or weak correlation with swollen joint count (0.18–0.20), tender joint count (0.12–0.29), LEI (–0.04 to 0.24) and physician global assessment (0.35–0.43); moderate correlation with fatigue (both −0.56); and strong correlation with patient global assessment of disease activity (0.62–0.69) and patient-reported pain (0.66–0.70). Similar correlations were observed for ASDAS. Axial involvement versus non-involvement was associated with higher BASDAI scores and ASDAS (all β ≥ 0.5), without differences between instruments; longitudinal associations between swollen joint count (β ≤ 0.06)/LEI (β ≤ 0.19) and BASDAI/ASDAS were clinically unimportant. Conclusion BASDAI and ASDAS performed similarly in patients with active PsA and axial involvement, independent of peripheral disease involvement, supporting their performance in assessing axial disease activity. Trial registration ClinicalTrials.gov, http://clinicaltrials.gov , NCT03162796 and NCT03158285. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Different Immunologic Profiles Are Associated With Distinct Clinical Phenotypes in Longitudinally Observed Patients With Systemic Lupus Erythematosus.

Author

Manion, Kieran, Muñoz‐Grajales, Carolina, Kim, Michael, Atenafu, Eshetu, Faheem, Zoha, Gladman, Dafna D., Urowitz, Murray, Touma, Zahi, and Wither, Joan E.

Subjects
SYSTEMIC lupus erythematosus treatment, FLOW cytometry, PARAMETERS (Statistics), SYSTEMIC lupus erythematosus, DECISION making in clinical medicine, LONGITUDINAL method, MATHEMATICAL statistics, T helper cells, PHENOTYPES, NONPARAMETRIC statistics, B cells, SYMPTOMS
Abstract

Objective: The aim of this study was to determine the immunologic profile associated with disease flares in patients with systemic lupus erythematosus (SLE) and to investigate the clinical significance of any differences observed between patients during and following a flare. Methods: Multiparameter flow cytometry was used to examine 47 immune populations within the peripheral blood of 16 healthy controls, 25 patients with clinically quiescent SLE, and 46 patients with SLE experiencing a flare at baseline and at 6‐ and 12‐month follow‐up visits. Unsupervised clustering was used to identify patients with similar immune profiles and to track changes over time. Parametric or nonparametric statistics were used when appropriate to assess the association of cellular phenotypes with clinical and laboratory parameters. Results: Five clusters of patients were identified that variably contained patients with active and quiescent SLE, and that had distinct clinical phenotypes. Patients characterized by increased T peripheral helper, activated B, and age‐associated B cells were the most likely to be flaring at baseline, as well as the most likely to remain active or flare over the subsequent year if they acquired or retained this phenotype at follow‐up. In contrast, patients who had increased T helper (Th) cells in the absence of B cell changes, or who had increased Th1 cells and innate immune populations, mostly developed quiescent SLE on follow‐up. A significant proportion of patients with SLE had depletion of many immune populations at flare and only showed increases in these populations post‐flare. Conclusion: Cellular phenotyping of patients with SLE reveals several distinct immunologic profiles that may help to stratify patients with regard to prognosis and treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications

Author

Bernatsky, Sasha, Ramsey‐Goldman, Rosalind, Urowitz, Murray B., Hanly, John G., Gordon, Caroline, Petri, Michelle A., Ginzler, Ellen M., Wallace, Daniel J., Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Dooley, Mary Anne, Peschken, Christine A., Isenberg, David A., Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, S. Sam, van Vollenhoven, Ronald, Nived, Ola, Kamen, Diane L., Aranow, Cynthia, Ruiz‐Irastorza, Guillermo, Sánchez‐Guerrero, Jorge, Gladman, Dafna D., Fortin, Paul R., Alarcón, Graciela S., Merrill, Joan T., Kalunian, Kenneth C., Ramos‐Casals, Manuel, Steinsson, Kristjan, Zoma, Asad, Askanase, Anca, Khamashta, Munther A., Bruce, Ian, Inanc, Murat, and Clarke, Ann E.

Published
2021
Full Text
View/download PDF

40. Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment.

Author

Muñoz-Grajales, Carolina, Barraclough, Michelle L., Diaz-Martinez, Juan P., Jiandong Su, Bingham, Kathleen, Kakvan, Mahta, Kretzmann, Roberta Pozzi, Tartaglia, Maria Carmela, Ruttan, Lesley, Choi, May Y., Appenzeller, Simone, Marzouk, Sherief, Bonilla, Dennisse, Katz, Patricia, Beaton, Dorcas, Green, Robin, Gladman, Dafna D., Wither, Joan, and Touma, Zahi

Subjects
SYSTEMIC lupus erythematosus, MATRIX metalloproteinases, COGNITION disorders
Abstract

Objective: Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Despite its frequency, we have a limited understanding of the underlying immune mechanisms, resulting in a lack of pathways to target. This study aims to bridge this gap by investigating differences in serum analyte levels in SLE patients based on their cognitive performance, independently from the attribution to SLE, and exploring the potential for various serum analytes to differentiate between SLE patients with and without CI. Methods: Two hundred ninety individuals aged 18-65 years who met the 2019-EULAR/ACR classification criteria for SLE were included. Cognitive function was measured utilizing the adapted ACR-Neuropsychological Battery (ACR-NB). CI was defined as a z-score of =-1.5 in two or more domains. The serum levels of nine analytes were measured using ELISA. The data were randomly partitioned into a training (70%) and a test (30%) sets. Differences in the analyte levels between patients with and without CI were determined; and their ability to discriminate CI from non-CI was evaluated. Results: Of 290 patients, 40% (n=116) had CI. Serum levels of S100A8/A9 and MMP-9, were significantly higher in patients with CI (p=0.006 and p=0.036, respectively). For most domains of the ACR-NB, patients with CI had higher S100A8/A9 serum levels than those without. Similarly, S100A8/A9 had a negative relationship with multiple CI tests and the highest AUC (0.74, 95%CI: 0.66-0.88) to differentiate between patients with and without CI. Conclusion: In this large cohort of well-characterized SLE patients, serum S100A8/A9 and MMP-9 were elevated in patients with CI. S100A8/A9 had the greatest discriminatory ability in differentiating between patients with and without CI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Derivation and Internal Validation of a Disease-Specific Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis.

Author

Colaco, Keith, Ker-Ai Lee, Akhtari, Shadi, Winer, Raz, Chandran, Vinod, Harvey, Paula, Cook, Richard J., Piguet, Vincent, Gladman, Dafna D., and Eder, Lihi

Subjects
MYOCARDIAL infarction risk factors, CARDIOVASCULAR disease prevention, HEART failure risk factors, CARDIOVASCULAR disease related mortality, CARDIOVASCULAR diseases risk factors, PSORIATIC arthritis, PSORIASIS, CONFIDENCE intervals, RESEARCH methodology, MAJOR adverse cardiovascular events, MULTIPLE regression analysis, NONSTEROIDAL anti-inflammatory agents, REGRESSION analysis, ACQUISITION of data, ANGINA pectoris, RISK assessment, SEVERITY of illness index, ANTIRHEUMATIC agents, THEORY, RESEARCH funding, DESCRIPTIVE statistics, QUESTIONNAIRES, MEDICAL records, MYOCARDIAL revascularization, BLOOD sedimentation, HEALTH behavior, PREDICTION models, SENSITIVITY & specificity (Statistics), RECEIVER operating characteristic curves, DATA analysis software, LONGITUDINAL method, BEHAVIOR modification, DISEASE risk factors, DISEASE complications
Abstract

Objective. To address suboptimal cardiovascular risk prediction in patients with psoriatic disease (PsD), we developed and internally validated a five-year disease-specific cardiovascular risk prediction model. Methods. We analyzed data from a prospective cohort of participants with PsD without a history of cardiovascular events. Traditional cardiovascular risk factors and PsD-related measures of disease activity were considered as potential predictors. The study outcome included nonfatal and fatal cardiovascular events. A base prediction model included 10 traditional cardiovascular risk factors. Eight PsD-related factors were assessed by adding them to the base model to create expanded models, which were controlled for PsD therapies. Variable selection was performed using Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression with 10-fold cross-validation. Model performance was assessed using measures of discrimination and calibration and measures of sensitivity and specificity. Results. Between 1992 and 2020, 85 of 1,336 participants developed cardiovascular events. Discrimination of the base model (with traditional cardiovascular risk factors alone) was excellent, with an area under the receiver operator characteristic curve (AUC) of 85.5 (95% confidence interval [CI] 81.9–89.1). Optimal models did not select any of the tested disease-specific factors. In a sensitivity analysis, which excluded lipid lowering and antihypertensive treatments, the number of damaged joints was selected in the expanded model. However, this model did not improve risk discrimination compared to the base model (AUC 85.5, 95% CI 82.0–89.1). Conclusion. Traditional cardiovascular risk factors alone are effective in predicting cardiovascular risk in patients with PsD. A risk score based on these factors performed well, indicating excellent discrimination and calibration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Author

Fanouriakis, Antonis, Kostopoulou, Myrto, Andersen, Jeanette, Aringer, Martin, Arnaud, Laurent, Bae, Sang- Cheol, Boletis, John, Bruce, Ian N., Cervera, Ricard, Dörner, Andrea Doria Thomas, Furie, Richard A., Gladman, Dafna D., Houssiau, Frederic A., Inês, Luís Sousa, Jayne, David, Kouloumas, Marios, Kovács, László, Mok, Chi Chiu, Morand, Eric F., and Moroni, Gabriella

Published
2024
Full Text
View/download PDF

44. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.

Author

Coates, Laura C., Landewé, Robert, McInnes, Iain B., Mease, Philip J., Ritchlin, Christopher T., Yoshiya Tanaka, Akihiko Asahina, Behrens, Frank, Gladman, Dafna D., Gossec, Laure, Orbai, Ana-Maria, Gottlieb, Alice B., Warren, Richard B., Ink, Barbara, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, and Merola, Joseph F.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results